Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

Benzinga_recent_news02:33

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589499814?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-06 02:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589499814","market":"hk","top_or_hot":-1,"title":"Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?","media":"Benzinga_recent_news","content":"<div>\n<p>Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-06 02:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal","article_id":"2589499814","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49238445/why-is-adaptive-biotechnologies-stock-trading-lower-after-nateras-over-400-million-deal","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589499814","pubTimestamp":1764959580,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Adaptive Biotechnologies shares fall as Natera's Foresight acquisition heightens MRD competition and tempers recent takeover speculation.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4082":"医疗保健设备","LU0058720904.USD":"联博国际健康护理基金A","BK4592":"伊斯兰概念","ASH":"Ashland","BK4504":"桥水持仓","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4109":"特种化学制品","BK4566":"资本集团","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4588":"碎股","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","ADPT":"Adaptive Biotechnologies Corp","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4121":"生命科学工具和服务","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","ABT":"雅培","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4139":"生物科技","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","BK4568":"美国抗疫概念","NTRA":"Natera, Inc.","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","EXAS":"精密科学","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD"},"translate_title":"为什么Natera超过4亿美元的交易后Adaptive Biotechnologies股票交易走低？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1,"ADPT":1,"EXAS":1,"ABT":1,"NTRA":1.5},"content_text":"Adaptive Biotechnologies Corporation (NASDAQ:ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ:NTRA) acquisition of cancer diagnostics firm Foresight Diagnostics for $275 million upfront and up to $175 million in additional earnouts tied to revenue- and reimbursement-based milestones.\n\"This acquisition reinforces Natera's position at the forefront of precision oncology,\" said Steve Chapman, chief executive officer of Natera.\nWilliam Blair writes that Adaptive Biotechnologies’ stock has been weak in recent sessions as fears over Natera's entrance into the blood-cancer MRD market emerged.\nOn Wednesday, Natera issued a press release highlighting four studies being presented at the 2025 American Society of Hematology (ASH) Annual Meeting, including for use in diffuse large B-cell lymphoma (DLBCL) and other lymphomas and multiple myeloma.\nNow with Foresight, analyst Andrew F. Brackmann writes that Natera is expected to accelerate its expansion into blood-cancer MRD with Foresight's CLARITY MRD test.\nWhile Adaptive has seen some competitive noise from Natera, with Signatera used in DLBCL, it has not seen competitive pressure from Foresight in clinical use.\nAlso Read: Abbott’s $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics\nThe deal not only raises competitive risk for a stock already trading at 10x expected 2026 MRD sales, but it also takes another potential buyer out of the mix.\nAdaptive's shares jumped more than 20% after the Abbott Laboratories (NYSE:ABT) and Exact Sciences Corp‘s (NASDAQ:EXAS) $23 billion deal on speculation that it could be an acquisition target.\nWith Natera now buying a competing asset, some of that M&A premium is likely to unwind.\nADPT Price Action: Adaptive Biotechnologies shares were down 12.63% at $15.25 at the time of publication on Friday, according to Benzinga Pro data.\nRead Next:\nPhoto: jittawit21/Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589499814","isCrawlerRequest":true}